Coverage for methadone and no prior authorizations for Vivitrol and Suboxone, two of the most common medication-assisted treatments.
No member cost-sharing for injectable and nasal spray formulations of naloxone and Narcan.
A robust network of nearly 100 substance abuse rehabilitation facilities and more than 5,000 behavioral health providers.
The current opioid epidemic in the United States is the worst drug crisis in our nation's history. Each day, thousands of people begin to misuse opioids and many of them will join the millions of Americans already suffering from addiction.
Independence is committed to turning the tide on opioid addiction and overdose. We are keenly focused on the prevention and treatment of this crisis. We have become a nationally recognized leader in this fight by examining the causes and implementing viable and sustainable solutions, including:
In addition, we give our network providers the tools, information, and resources they need to care for their patients who are prescribed opioids, and we work with pharmacists to manage and monitor members' prescription usage.
We are glad to report that these efforts are making measurable progress. Since 2015 the number of members using opioids and prescriptions for opioids has dropped more than a third. Read our white paper.
Between 2014 and 2018, Independence has seen a major reduction in members using opioids, opioid prescription claims processed, and opioid dosages prescribed.
To help decrease the number of members using opioids and to help those struggling with addiction, we have compiled a list of opioid and substance abuse resources with links to drug take-back sites, contact information for prevention and addiction assistance, and useful information from the Centers for Disease Control and Prevention.
Moreover, Independence health plans include coverage for:
Dr. Richard Snyder, EVP and Chief Medical Officer at Independence Blue Cross, and Dr. Matthew Austin, Director of Joint Replacement Services at Rothman Institute discuss how embracing alternative treatment methods for pain and collaborating with the community is helping to slow the growth of the opioid crisis.
Prior authorization required on all high-dose opioids.
Added prior authorization to >90 MED.
Cumulative 5-day supply limit.
Prior authorization on all pain patches.
Removed prior authorization on all buprenorphine products.
Safety edit messaging for benzodiazepine/opioid utilization.
90 MME threshold.
Brand OxyContin®, oxycodone ER tablet, and Xtampza® XR coverage changes.
Through its Support Treatment and Overdose Prevention (STOP) initiative, the Independence Blue Cross Foundation works to increase awareness and access to effective community-based opioid treatment and prevention.